{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:53:53Z","timestamp":1785790433601,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The current incidence, diagnostic policy, management, and outcome of VOD\/SOS at EBMT centers were studied. All centers that had performed allogeneic HSCTs in adult patients within one defined year were invited to the study. Seventy-one centers participated with a total of 2886 allogeneic transplantations and 93 cases of VOD\/SOS in 2018. The cumulative incidence of VOD\/SOS at day 21 was 1.8% and at day 100 2.4%. Of 67 cases with detailed data, 52 were classical and 15 (22%) late onset (&gt;day 21). According to the EBMT criteria, 65\/67 patients had at least two VOD\/SOS risk factors. The severity grades were: mild 0, moderate 3, severe 29, very severe 35. Fifty-four patients were treated with defibrotide. VOD\/SOS resolved in 58% of the patients, 3\/3 with moderate, 22\/28 with severe, and 12\/33 with very severe grade (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). By day 100, 57% of the patients were alive; 3\/3 with moderate, 22\/29 with severe, and 13\/35 with very severe VOD\/SOS (<jats:italic>p<\/jats:italic>\u2009=\u20090.002). In conclusion, the incidence of VOD\/SOS was low. Severe and very severe grades dominated. Very severe grade predicted poor outcome compared to severe grade further supporting the concept of early diagnosis and treatment to avoid a dismal outcome.<\/jats:p>","DOI":"10.1038\/s41409-023-02077-2","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T07:01:42Z","timestamp":1691823702000},"page":"1209-1214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Current incidence, severity, and management of veno-occlusive disease\/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-8345","authenticated-orcid":false,"given":"Tapani","family":"Ruutu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3829-0088","authenticated-orcid":false,"given":"Christophe","family":"Peczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Houhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Polge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4332-0114","authenticated-orcid":false,"given":"Ivan","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-9001","authenticated-orcid":false,"given":"Nina","family":"Salooja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7568-8239","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2039-8557","authenticated-orcid":false,"given":"Mutlu","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpu","family":"Salmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annoek E. C.","family":"Broers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-5980","authenticated-orcid":false,"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazimierz","family":"Halaburda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6204-977X","authenticated-orcid":false,"given":"Tsila","family":"Zuckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Labussi\u00e8re-Wallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-8180","authenticated-orcid":false,"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-1735","authenticated-orcid":false,"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-8025","authenticated-orcid":false,"given":"Zinaida","family":"Peri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"2077_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/bmt.2015.52","volume":"50","author":"M Mohty","year":"2015","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives \u2013 a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:781\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"2077_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppel","year":"2010","unstructured":"Coppel JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2077_CR3","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2011.06.006","volume":"17","author":"E Carreras","year":"2011","unstructured":"Carreras E, Diaz-Bey\u00e1 M, Rosi\u00f1ol L, Martinez C, Fern\u00e1ndez-Avil\u00e9s F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011;17:1713\u201320.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2077_CR4","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1016\/j.bbmt.2018.06.013","volume":"24","author":"C Strouse","year":"2018","unstructured":"Strouse C, Zhang Y, Zhang M-J, DiGilio A, Pasquini M, Horowitz MM, et al. Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant. 2018;24:2072\u201380.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2077_CR5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41409-019-0474-8","volume":"54","author":"P Richardson","year":"2019","unstructured":"Richardson P, Aggarwal S, Topaloglu O, Villa KF, Corbacioglu S. Systematic review of defibrotide studies in the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS). Bone Marrow Transplant. 2019;54:1951\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"2077_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.00489","volume":"11","author":"F Bonifazi","year":"2020","unstructured":"Bonifazi F, Barbato F, Ravaioli F, Sessa M, Delfrancesco I, Arpinati M, et al. Diagnosis and treatment of VOD\/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:1\u201313.","journal-title":"Front Immunol"},{"key":"2077_CR7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/bjh.16557","volume":"190","author":"MS Cairo","year":"2020","unstructured":"Cairo MS, Cooke KR, Lazarus HM, Chao N. Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS\/VOD after haematopoietic cell transplantation. Br J Haematol. 2020;190:822\u201336.","journal-title":"Br J Haematol"},{"key":"2077_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/bmt.2014.168","volume":"49","author":"PD Tsirigotis","year":"2014","unstructured":"Tsirigotis PD, Resnick IB, Avni B, Grisariu S, Stepensky P, Or R, et al. Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen. Bone Marrow Transplant. 2014;49:1389\u201392.","journal-title":"Bone Marrow Transplant"},{"key":"2077_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906\u201312.","journal-title":"Bone Marrow Transplant"},{"key":"2077_CR10","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"25","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;25:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2077_CR11","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KGMM Alberti","year":"2009","unstructured":"Alberti KGMM, Eckel EH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120:1640\u20135.","journal-title":"Circulation"},{"key":"2077_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41409-020-01135-3","volume":"56","author":"AH Bazarbachi","year":"2021","unstructured":"Bazarbachi AH, Al Hamed R, Labopin M, Halaburda K, Labussiere H, Bernasconi P, et al. Underdiagnosed veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2021;56:917\u201327.","journal-title":"Bone Marrow Transplant"},{"key":"2077_CR13","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.bbmt.2007.08.002","volume":"13","author":"E Carreras","year":"2007","unstructured":"Carreras E, Rosi\u00f1ol L, Terol MJ, Alegre A, de Arriba F, Garc\u00eda-Lara\u00f1a J, et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant. 2007;13:1448\u201354.","journal-title":"Biol Blood Marrow Transplant"},{"key":"2077_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/bjh.14727","volume":"178","author":"PG Richardson","year":"2017","unstructured":"Richardson PG, Smith AR, Triplett BM, Kernan NA, Grupp SA, Antin JH, et al. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease\/sinusoidal obstruction syndrome improves day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017;178:112\u20138.","journal-title":"Br J Haematol"},{"key":"2077_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M, Balduzzi A, Cesaro S, Dalle J-H, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2018;53:138\u201345.","journal-title":"Bone Marrow Transplant"},{"key":"2077_CR16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR, Arai S, Triplett B, Antin JH, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol. 2018;181:816\u201327.","journal-title":"Br J Haematol"},{"key":"2077_CR17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/17474124.2017.1370372","volume":"11","author":"S Corbacioglu","year":"2017","unstructured":"Corbacioglu S, Richardson PG. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. Exp Rev Gastroenterol Hepatol. 2017;11:885\u201398.","journal-title":"Exp Rev Gastroenterol Hepatol"},{"issue":"Supplement 1","key":"2077_CR18","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1182\/blood-2021-147302","volume":"138","author":"M Mohty","year":"2021","unstructured":"Mohty M, Blaise D, Peffault de Latour R, Labopin M, Detrait M, Girault S. Final long-term results from the Defifrance registry study: efficacy and safety of defibrotide for the treatment of severe\/very severe veno-occlusive disease\/sinusoidal obstruction syndrome after hematopoietic cell transplantation. Blood. 2021;138 Supplement 1:1789.","journal-title":"Blood."},{"key":"2077_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/bloodadvances.2021005410","volume":"6","author":"M Nauffal","year":"2022","unstructured":"Nauffal M, Kim HT, Richardson PG, Soiffer RJ, Antin JH, Cutler C, et al. Defibrotide: real-world management of veno-occlusive disease\/sinusoidal obsructive syndrome after stem cell transplant. Blood Adv. 2022;6:181\u20138.","journal-title":"Blood Adv"},{"key":"2077_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","volume":"54","author":"J-H Yoon","year":"2019","unstructured":"Yoon J-H, Yoo KH, Sung KW, Jung CW, Kim JS, Hahn SM, et al. Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome\/veno-occlusive diseases (SOS\/VOD). Bone Marrow Transplant. 2019;54:1361\u20138.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02077-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T08:03:13Z","timestamp":1698912193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-023-02077-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1038\/s41409-023-02077-2","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"28 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM received research support and honoraria for lectures from Amgen, Astellas, BMS, GSK, Janssen, Jazz Pharmaceuticals, Pfizer, Takeda, Oncopeptides, Adaptive, and Sanofi. NK served as consultant and received honoraria from Jazz Pharmaceuticals. OP received research and travel support and served as a member of advisory board of Jazz Pharmaceuticals. HS reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, both paid to her institution. She has received non-financial support from Gilead, Pfizer, the EBMT (European Society for Blood and Marrow Transplantation) and the CIBMTR (Center for International Bone Marrow Transplantation Research). She has also frequently served as a volunteer for EBMT, CIBMTR and EUPATI. RFD received honoraria as speaker for Jazz Pharmaceuticals. TR, IM, TS, JHB, AR, and GB received honoraria from Jazz Pharmaceuticals. CP, MH, EP, NS, JP, GGW, AG, SS, MA, US, AECB, JM, KH, TZ, HL-W, CK, and ZP declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}